Erasca’s pan-RAS pill ERAS-0015 drew confirmed responses in 44% of 25 previously treated pancreatic cancer patients at 32 mg, its chosen dose. The Phase 1 trial has no control group, and response rate is a secondary endpoint. Single-arm, early and company-reported, so it cannot show benefit over other treatment. Erasca plans a first-line pancreatic Phase 3 in the first half of 2027.
↳ Biotech & Pharma's story 01 today, marked Must read.
The S&P 500 closes in correction. The S&P 500 fell 3.70% to 6,910.39, 11.62% below its 10.06 record close. The Nasdaq 100 fell 5.61% and the VIX closed at 35.89. The selling was heaviest in chips and memory, the companies closest to AI spending. Consumer staples and health care rose, per Reuters.
↳ AI & Technology's story 01 today, marked Must read.
Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer. In 61 patients, 60.7% had a confirmed response and median progression-free survival was 12.8 months. Another single-arm result. The randomized test against chemotherapy alone, RASolute 303, has not read out.
↳ Biotech & Pharma's story 02 today, marked Must read.
Anthropic closes its IPO; the stock falls 8.98%. Anthropic says gross proceeds were about $93.5 billion from the offering and about $26.0 billion from a private placement. ANT’s last regular-session trade was $88.445. The stock is still above its $83 offer price. Some analysts say the deal may have pulled money from other tech; we found no fund-flow data showing it.
↳ AI & Technology's story 02 today, marked Must read.
Actinogen’s pivotal trial of Xanamem in Alzheimer’s disease missed its primary endpoint. The benefit on CDR-SB at week 36 was 0.10 points versus placebo, p = 0.65. The company points to a prespecified subgroup of older patients, but a subgroup after a missed primary is a reason for a new trial, not proof.
↳ Biotech & Pharma's story 03 today, marked Must read.
Four intelligence briefs covering biotech, AI and technology, global affairs and life. Key claims linked to sources, counterarguments made explicit, forecasts tracked publicly, and corrections recorded.